Results 161 to 170 of about 19,663 (194)
Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. [PDF]
Cancer LettHinz TK +11 more
europepmc +1 more source
A meta-analysis of the impact of different ALK variants on targeted therapy efficacy in advanced non-small cell lung cancer. [PDF]
Front OncolGu Z, Chen Z, Lai Q, Lin D.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2014
Crizotinib is an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases (RTK) C-Met, ALK and ROS1. There is a robust effectiveness in non-small-cell lung cancer (NSCLC) harbouring EML4-ALK-rearrangements resulting in constitutional activation of the ALK-RTK.
David F, Heigener, Martin, Reck
+7 more sources
Crizotinib is an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases (RTK) C-Met, ALK and ROS1. There is a robust effectiveness in non-small-cell lung cancer (NSCLC) harbouring EML4-ALK-rearrangements resulting in constitutional activation of the ALK-RTK.
David F, Heigener, Martin, Reck
+7 more sources
Renal Injury during Long-Term Crizotinib Therapy
International Journal of Molecular Sciences, 2018 Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown.
Esteban C Gabazza +2 more
exaly +2 more sources
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer [PDF]
Journal of Thoracic Oncology, 2013 BackgroundAnaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is markedly sensitive to the ALK inhibitor crizotinib. However, acquired resistance to crizotinib is inevitable through several mechanisms. Therefore, this study was
Dong-Wan Kim, Dae-Seog Heo, Tae Min Kim
exaly +2 more sources